Immunovant, Inc. IMVT
33.30
(0.70)
(2.06%)
as of 25 Sep
- Market cap
- $7.1B
- P/E
- 0.0×
Follow IMVT
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(95.93%) | (69.35%) | (64.82%) | (80.10%) | |
| (84.59%) | (63.01%) | (58.34%) | (71.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(90.95%) | (47.50%) | (59.85%) | (73.28%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.48) | (2.33) | (2.24) | (2.02) | |
Free Cash Flow |
(430.95) | (422.89) | (407.89) | (414.30) | |
Capital Expenditures |
— | — | (0.58) | — | |
| Other line items | |||||
Cash ROIC |
(41.38%) | (21.35%) | (23.21%) | (27.02%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.91 | 0.81 | 0.77 | |
Depreciation/Fixed assets |
0.66 | 0.79 | 0.92 | 1.12 | |
Capex/Depreciation |
0.00 | 0.00 | (1.43) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.48) | (2.33) | (2.23) | (2.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates